These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 39313158)
21. Week 96 Results of Switching from Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide among HIV/Hepatitis B Virus-Coinfected Patients. Huang YS; Cheng CY; Sun HY; Cheng SH; Lu PL; Lee CH; Lee YT; Tsai HC; Yang CJ; Liu CE; Liou BH; Lin SP; Huang SH; Ho MW; Tang HJ; Hung CC; Microbiol Spectr; 2023 Jun; 11(3):e0512522. PubMed ID: 36988457 [TBL] [Abstract][Full Text] [Related]
22. Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy. Hafkin JS; Osborn MK; Localio AR; Amorosa VK; Kostman JR; Stern JJ; De La Torre P; Mounzer K; Frank I; Gross R; Chang KM; Lo Re V J Viral Hepat; 2014 Apr; 21(4):288-96. PubMed ID: 24597697 [TBL] [Abstract][Full Text] [Related]
23. Effects of long-term tenofovir-based combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversity. Audsley J; Bent SJ; Littlejohn M; Avihingsanon A; Matthews G; Bowden S; Bayliss J; Luciani F; Yuen L; Fairley CK; Locarnini S; Lewin SR; Sasadeusz J AIDS; 2016 Jun; 30(10):1597-606. PubMed ID: 26950313 [TBL] [Abstract][Full Text] [Related]
24. Intensification of treatment with pegylated interferon alfa in patients coinfected with HIV and HBV genotype H or G being treated with a tenofovir/emtricitabine-containing regimen. Mata-Marín JA; Mata-Marín LA; Arroyo-Anduiza CI; Huerta-García G; Sandoval-Ramirez JL; Manjarrez-Tellez B; Gaytán-Martínez JE Hepatogastroenterology; 2014; 61(133):1187-91. PubMed ID: 25436280 [TBL] [Abstract][Full Text] [Related]
25. Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G. Lada O; Gervais A; Branger M; Peytavin G; Roquebert B; Collin G; Fraqueiro G; Moucari R; Hamet G; Martinot-Peignoux M; Matheron S; Marcellin P Liver Int; 2012 Jan; 32(1):93-101. PubMed ID: 22097898 [TBL] [Abstract][Full Text] [Related]
26. Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy. Lewin SR; Ribeiro RM; Avihingsanon A; Bowden S; Matthews G; Marks P; Locarnini SA; Ruxrungtham K; Perelson AS; Dore GJ Hepatology; 2009 Apr; 49(4):1113-21. PubMed ID: 19115219 [TBL] [Abstract][Full Text] [Related]
27. Brief Report: Relationship Between ABCC4 SNPs and Hepatitis B Virus Suppression During Tenofovir-Containing Antiretroviral Therapy in Patients With HIV/HBV Coinfection. Archampong T; Ojewale O; Bears K; Chen Y; Lartey M; Sagoe KW; Obo-Akwa A; Gong Y; Langaee T; Kwara A J Acquir Immune Defic Syndr; 2019 Dec; 82(4):421-425. PubMed ID: 31335591 [TBL] [Abstract][Full Text] [Related]
28. Hepatitis B viremia in HIV-coinfected individuals under antiretroviral therapy. Weissmann L; Picone CM; Gouvêa MSG; Ferreira PRA; Viana MSVB; Pinho JRR; Cassenote AJF; Segurado AC Braz J Infect Dis; 2019; 23(6):441-450. PubMed ID: 31715124 [TBL] [Abstract][Full Text] [Related]
29. Hepatitis B Virus (HBV) Load Response to 2 Antiviral Regimens, Tenofovir/Lamivudine and Lamivudine, in HIV/ HBV-Coinfected Pregnant Women in Guangxi, China: The Tenofovir in Pregnancy (TiP) Study. Wang L; Wiener J; Bulterys M; Wei X; Chen L; Liu W; Liang S; Shepard C; Wang L; Wang A; Zhang F; Kourtis AP J Infect Dis; 2016 Dec; 214(11):1695-1699. PubMed ID: 27658693 [TBL] [Abstract][Full Text] [Related]
30. Association of tenofovir diphosphate and lamivudine triphosphate concentrations with HIV and hepatitis B virus viral suppression. Lartey M; Ganu VJ; Tachi K; Yang H; Anderson PL; Langaee T; Ojewale O; Boamah I; Obo-Akwa A; Antwi K; Bushman LR; Ellison L; Kwara A AIDS; 2024 Mar; 38(3):351-362. PubMed ID: 37861682 [TBL] [Abstract][Full Text] [Related]
31. Proportion and factors associated with Hepatitis B viremia in antiretroviral treatment naïve and experienced HIV co-infected Ghanaian patients. Archampong TN; Lartey M; Sagoe KW; Obo-Akwa A; Kenu E; Gillani FS; Yang H; Boamah I; Flanigan T; Kwara A BMC Infect Dis; 2016 Jan; 16():14. PubMed ID: 26759172 [TBL] [Abstract][Full Text] [Related]
32. Virological responses to lamivudine or emtricitabine when combined with tenofovir and a protease inhibitor in treatment-naïve HIV-1-infected patients in the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort. Rokx C; Gras L; van de Vijver D; Verbon A; Rijnders B; HIV Med; 2016 Sep; 17(8):571-80. PubMed ID: 26842457 [TBL] [Abstract][Full Text] [Related]
33. Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals. Matthews GV; Seaberg E; Dore GJ; Bowden S; Lewin SR; Sasadeusz J; Marks P; Goodman Z; Philp FH; Tang Y; Locarnini S; Thio CL AIDS; 2009 Aug; 23(13):1707-15. PubMed ID: 19584701 [TBL] [Abstract][Full Text] [Related]
34. Liver Fibrosis by Transient Elastography and Virologic Outcomes After Introduction of Tenofovir in Lamivudine-Experienced Adults With HIV and Hepatitis B Virus Coinfection in Ghana. Stockdale AJ; Phillips RO; Beloukas A; Appiah LT; Chadwick D; Bhagani S; Bonnett L; Sarfo FS; Dusheiko G; Geretti AM; Clin Infect Dis; 2015 Sep; 61(6):883-91. PubMed ID: 26021992 [TBL] [Abstract][Full Text] [Related]
35. Comparative effectiveness of anti-viral drugs with dual activity for treating hepatitis B and HIV co-infected patients: a network meta-analysis. Naing C; Poovorawan Y; Tong KS BMC Infect Dis; 2018 Nov; 18(1):564. PubMed ID: 30428847 [TBL] [Abstract][Full Text] [Related]
36. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand. Matthews GV; Avihingsanon A; Lewin SR; Amin J; Rerknimitr R; Petcharapirat P; Marks P; Sasadeusz J; Cooper DA; Bowden S; Locarnini S; Ruxrungtham K; Dore GJ Hepatology; 2008 Oct; 48(4):1062-9. PubMed ID: 18697216 [TBL] [Abstract][Full Text] [Related]
37. Management of the Hepatitis B Virus/HIV-Coinfected Patient. Sherman KE Top Antivir Med; 2015; 23(3):111-4. PubMed ID: 26518394 [TBL] [Abstract][Full Text] [Related]
38. Factors associated with delayed hepatitis B viral suppression on tenofovir among patients coinfected with HBV-HIV in the CNICS cohort. Kim HN; Rodriguez CV; Van Rompaey S; Eron JJ; Thio CL; Crane HM; Overton ET; Saag MS; Martin J; Geng E; Mugavero M; Rodriguez B; Mathews WC; Boswell S; Moore R; Kitahata MM; J Acquir Immune Defic Syndr; 2014 May; 66(1):96-101. PubMed ID: 24500175 [TBL] [Abstract][Full Text] [Related]
39. Comparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIV-HBV-coinfected patients. Lacombe K; Gozlan J; Boyd A; Boelle PY; Bonnard P; Molina JM; Miailhes P; Lascoux-Combe C; Serfaty L; Zoulim F; Girard PM Antivir Ther; 2008; 13(5):705-13. PubMed ID: 18771054 [TBL] [Abstract][Full Text] [Related]
40. Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression. Huang WC; Huang CK; Huang SH; Lin SW; Ou ST; Chen YT; Chen YW; Chang SY; Liu WC; Sun HY; Hung CC J Microbiol Immunol Infect; 2021 Oct; 54(5):944-951. PubMed ID: 32675042 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]